Astrazeneca (AZN) Net Equity Issued and Repurchased (2009 - 2026)

Astrazeneca has reported Net Equity Issued and Repurchased for 18 years, with the latest figure at $6.0 million in Q2 2026.

• On a quarterly basis, Net Equity Issued and Repurchased rose 50.0% year-over-year to $6.0 million in Q2 2026; TTM through Jun 2026 was $44.0 million, a 12.82% increase from a year earlier, with the FY2025 full-year figure at $40.0 million, up 5.26% from the prior year.
• Net Equity Issued and Repurchased was $6.0 million for Q2 2026 at Astrazeneca, down from $10.0 million in the prior quarter.
• The five-year high for Net Equity Issued and Repurchased was $23.0 million in Q4 2024, with the low at $3.0 million in Q2 2022.
• Average Net Equity Issued and Repurchased over 5 years is $7.9 million, with a median of $5.0 million recorded in 2022.
• The sharpest annual moves came in 2022 and 2024: Net Equity Issued and Repurchased declined 25.0% in 2022, then surged 50.0% in 2024.
• Over 5 years, Net Equity Issued and Repurchased stood at $3.0 million in 2022, then soared by 33.33% to $4.0 million in 2023, then surged by 475.0% to $23.0 million in 2024, then changed by 0.0% to $23.0 million in 2025, then slumped by 73.91% to $6.0 million in 2026.
• The last three Net Equity Issued and Repurchased figures came in at $6.0 million (Q2 2026), $10.0 million (Q1 2026), and $23.0 million (Q4 2025), per Business Quant data.